Item 16. FORM 10-K SUMMARY

11K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Dated: February 23, 2022	Boston Scientific Corporation

	By:	/s/ Daniel J. Brennan

		Daniel J. Brennan
		Executive Vice President and Chief Financial Officer
		(duly authorized officer and principal financial officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.




Dated: February 23, 2022	By:	/s/ Daniel J. Brennan

		Daniel J. Brennan
		Executive Vice President and Chief Financial Officer
		(Principal Financial Officer)




Dated: February 23, 2022	By:	/s/ Michael F. Mahoney

		Michael F. Mahoney
		Director, Chairman of the Board, President and Chief Executive Officer
		(Principal Executive Officer)




Dated: February 23, 2022	By:	/s/ Jonathan R. Monson

		Jonathan R. Monson
		Vice President, Global Controller and Chief Accounting Officer
		(Principal Accounting Officer)




Dated: February 23, 2022	By:	/s/ Nelda J. Connors

		Nelda J. Connors
		Director




Dated: February 23, 2022	By:	/s/ Charles J. Dockendorff

		Charles J. Dockendorff
		Director




Dated: February 23, 2022	By:	/s/ Yoshiaki Fujimori

		Yoshiaki Fujimori
		Director




Dated: February 23, 2022	By:	/s/ Donna A. James

		Donna A. James
		Director




Dated: February 23, 2022	By:	/s/ Edward J. Ludwig

		Edward J. Ludwig
		Director




Dated: February 23, 2022	By:	/s/ David J. Roux

		David J. Roux
		Director




Dated: February 23, 2022	By:	/s/ John E. Sununu

		John E. Sununu
		Director




Dated: February 23, 2022	By:	/s/ David S. Wichmann

		David S. Wichmann
		Director




Dated: February 23, 2022	By:	/s/ Ellen M. Zane

		Ellen M. Zane
		Director

Schedule II

VALUATION AND QUALIFYING ACCOUNTS

(in millions)


Description	Balance at Beginning of Year		Cumulative effect adjustment for adoption of ASU 2016-13 (a)	Credit loss exposure (a)	Write-offs (c)	Balance at End of Year
Year Ended December 31, 2021:
Allowances for credit losses	$	105	n/a	28	(25)	$	108
Year Ended December 31, 2020:
Allowances for credit losses (b)	$	74	10	49	(27)	$	105
Year Ended December 31, 2019:
Allowances for uncollectible accounts	$	68	n/a	23	(17)	$	74

(a) Following the adoption of FASB ASC Topic 326 as of January 1, 2020, we record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. As a result of the adoption of FASB ASC Topic 326, we recorded a net reduction to opening retained earnings on January 1, 2020 related to the establishment of credit loss reserves on Trade accounts receivable and recorded a corresponding increase in the Allowance for credit losses, a contra Trade accounts receivable account. Prior period amounts have not been restated and are presented in accordance with FASB ASC Topic 310. Amounts shown within credit loss exposure above were established through selling, general and administrative expense.

(b) Beginning in 2020, Allowance for uncollectible accounts are referred to as Allowance for credit losses within our consolidated balance sheets.

Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES